Article Text

NIH Establishes New Center

Statistics from

The National Institutes of Health (NIH) announced the establishment of the National Center for Advancing Translational Sciences (NCATS). The new Center will be dedicated to advancing translational science and will work in coordination with partners in the regulatory, academic, nonprofit and private sectors to identify and overcome obstacles that slow the development of effective therapies. Funding for NCATS, which has a budget of $575 million, is primarily a reallocation of funds from programs previously located in the NIH Office of the Director, National Human Genome Research Institute, and National Center for Research Resources. The NIH reported that the funding ratio of basic and applied research will not be impacted by the establishment of NCATS.

To develop NCATS, the NIH is reorganizing a number of its preclinical and clinical translational science capabilities into an integrated scientific enterprise with new leadership and a new agenda. As announced by the NIH, the following programs will comprise NCATS:

  • Bridging Interventional Development Gaps, which makes available critical resources needed for the development of new therapeutic agents

  • Clinical and Translational Science Awards, which fund a national consortium of Medical research institutions working together to improve the way clinical and translational research is conducted nationwide

  • Cures Acceleration Network, which enables NCATS to fund research in new and Innovative ways

  • FDA-NIH Regulatory Science, which is an interagency partnership that aims to accelerate the development and use of better tools, standards and approaches for developing and evaluating diagnostic and therapeutic products

  • Office of Rare Diseases Research, which coordinates and supports rare diseases research

  • Components of the Molecular Libraries, which is an initiative that provides researchers with access to the large-scale screening capacity necessary to identify compounds that can be used as chemical probes to validate new therapeutic targets

  • Therapeutics for Rare and Neglected Diseases, which is a program to …

View Full Text

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.